EU Co. Obtains Smallpox Vaccine Order to Target Monkeypox

Shares of Danish vaccine company Bavarian Nordic A/S rose 70% after the company announced it had secured a contract for its smallpox vaccine IMVANEX® from an undisclosed European country for use in the treatment of new confirmed cases of monkeypox.

Denmark-based biotechnology company Bavarian Nordic A/S (BVNRY: OTC; BAVA: OMX), a fully integrated vaccine company focused on the development, manufacturing and commercialization of vaccines to treat cancer and infectious diseases, has announced today that “it has been awarded a contract with an undisclosed European country to supply its smallpox vaccine IMVANEX® in response to new cases of monkeypox evolving in May 2022.”

The report stated that on May 7, 2022, a person returning to Europe who had recently traveled to Nigeria where monkeypox is endemic was confirmed to have the disease. Since that first person was identified, twenty additional cases have been confirmed in England, Portugal and Spain and several other potential infections are under investigation.

Currently, the evidence is believed to indicate that these new infections were acquired locally and not while traveling outside of Europe. The report notes that so far only one case has been confirmed in the United States in a traveler from Canada, although no cases have yet been confirmed in Canada, but several possible cases are currently under investigation. ‘investigation.

The company said its smallpox vaccine, known and marketed as JYNNEOS® in the United States and as IMVAMUNE® in Canada, has also been approved for prolonged use in the monkeypox indication. The company pointed out that “the vaccine is approved in Europe as IMVANEX® for the smallpox indication only, but has already been supplied for off-label use in response to cases of monkeypox.”

Bavarian Nordic President and CEO Paul Chaplin said: “Although the full circumstances surrounding the current cases of monkeypox in Europe remain to be elucidated, the speed at which these have evolved, combined with the potential for infections beyond the initial undetected case calls for a swift and coordinated approach from health authorities, and we are happy to help in this emergency.”

“Infection control has been a high priority for societies during COVID-19, and this situation is an unfortunate reminder that we cannot let our guard down, but must continue to build and strengthen our disease preparedness. infections to keep the world open,” Chaplin said. added.

Bavarian Nordic did not provide specific details regarding the size of the vaccine order or the dollar amount of the transaction; however, the company has expressly stated that the order will not have a material impact on its financial forecast for the year 2022.

The society explained that “monkey pox is a rare but serious disease, which is endemic in central and western Africa”. The company added that “the disease is quite similar to human smallpox, although less severe with an estimated mortality rate of 1-10%.”

The disease was initially discovered in two monkey research colonies in 1958. Around this time, outbreaks of a smallpox-like disease were seen in the colonies and this is where the name monkeypox was derived from. The first identified human case occurred in 1970 in the Democratic Republic of the Congo as the country and the African continent were engaged in concentrated efforts to eradicate smallpox. Subsequently, the disease spread to people in several other countries in Central and West Africa. While most recorded cases have occurred in the Democratic Republic of Congo, historically there have been other documented cases outside of Africa in the UK, US, Israel and Singapore.

Bavarian Nordic is a fully integrated vaccine company headquartered in Denmark. The company is engaged in the development, manufacture and marketing of vaccines targeting the treatment of cancer and infectious diseases. The company has operations in Denmark, Germany, Switzerland and the United States. The company claimed that “it is a world leader in smallpox vaccines and is a long-term supplier to the U.S. government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox.”

The company’s portfolio also includes vaccines against tick-borne encephalitis (Encepur®) and rabies Rabipur® / RabAvert®), as well as a vaccine designed for Ebola (MVABEA®), which is licensed to Johnson & Johnson’s ( JNJ:NYSE) Janssen Pharmaceuticals. The Company’s investigational pipeline includes two additional vaccines entering the Phase 3 clinic this year, including a next-generation SARS-Co-V2 vaccine and a respiratory syncytial virus (RSV) vaccine.

Bavarian Nordic A/S has a market capitalization of approximately $2.04 billion with approximately 211.4 million shares outstanding. Shares of BVNRY opened nearly 40% higher today at $8.72 (+$2.47, +39.52%) from yesterday’s closing price of $6.25. The stock traded today between $8.45 and $10.85 per share and is currently trading at $10.75 (+$4.50, +72.00%).

You want to be the first to know about interesting information Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise’ reports newsletter.


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He himself or the members of his household hold shares in the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of the Streetwise Reports billboard: None. Click here for important information on referral fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is provided for informational purposes only and does not constitute a recommendation to buy or sell any securities.
4) The article does not constitute investment advice. Each reader is encouraged to consult their financial professional and any action taken by a reader as a result of the information presented here is their own responsibility. By opening this page, each reader accepts and consents to the full Streetwise Reports Terms of Service and Legal Notice. This article is not an investment solicitation. Streetwise Reports does not provide general or specific investment advice and information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the activities, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or their family members, as well as those interviewed for articles and interviews on the site, may take a long or short position in the titles mentioned. Directors, officers, employees or members of their immediate family are prohibited from making purchases and/or sales of such securities on the open market or otherwise from the time of the decision to publish an article until three days working days after the publication of the article. . The foregoing prohibition does not apply to articles that, in substance, merely restate previously published company announcements.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed healthcare professionals. Readers should always contact their healthcare professionals for medical advice.

Comments are closed.